drugset / Trial / NCT05342974

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

NCT05342974

NaSingle-groupOpen-labelOther

Summary

Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-49 days of pregnancy will receive an oral dose of atorvastatin (80 mg) to swallow at the clinic as well as taking atorvastatin (80 mg) daily for six additional days, with a return to clinic on day 8 after initial visit to take a dose of misoprostol (800 mcg). Additionally, follow-up visits will occur on approximately days 3, 8 and 11 for a clinician to perform an ultrasound to see if the abortion is complete.

Timeline

Start
2022-04-19
Primary completion
2023-12-31
Completion
2025-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg Oral
Background Misoprostol Other / unclassified 800 ug Intravenous

Indications

No indication recorded.